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Biomarker-guided treatments are needed in psychiatry, and 
previous data suggest oxidative stress may be a target in 
schizophrenia. A previous add-on trial with the antioxidant 
N-acetylcysteine (NAC) led to negative symptom reduc-
tions in chronic patients. We aim to study NAC’s impact 
on symptoms and neurocognition in early psychosis (EP) 
and to explore whether glutathione (GSH)/redox markers 
could represent valid biomarkers to guide treatment. In a 
double-blind, randomized, placebo-controlled trial in 63 
EP patients, we assessed the effect of NAC supplementa-
tion (2700 mg/day, 6 months) on PANSS, neurocognition, 
and redox markers (brain GSH [GSHmPFC], blood cells 
GSH levels [GSHBC], GSH peroxidase activity [GPxBC]). 
No changes in negative or positive symptoms or functional 
outcome were observed with NAC, but significant improve-
ments were found in favor of NAC on neurocognition (pro-
cessing speed). NAC also led to increases of GSHmPFC by 
23% (P = .005) and GSHBC by 19% (P = .05). In patients 
with high-baseline GPxBC compared to low-baseline GPxBC, 
subgroup explorations revealed a link between changes of 
positive symptoms and changes of redox status with NAC. 
In conclusion, NAC supplementation in a limited sample 
of EP patients did not improve negative symptoms, which 
were at modest baseline levels. However, NAC led to some 
neurocognitive improvements and an increase in brain GSH 
levels, indicating good target engagement. Blood GPx 
activity, a redox peripheral index associated with brain 
GSH levels, could help identify a subgroup of patients who 
improve their positive symptoms with NAC. Thus, future 
trials with antioxidants in EP should consider biomarker-
guided treatment.
Key words:  glutathione/glutathione peroxidase/ 
schizophrenia/MRS/prefrontal cortex/neurocognition
Introduction
While early intervention improves the treatment of psy-
chosis patients,1 full benefits of these strategies are ham-
pered by limited biological treatments. If  antipsychotics 
improve positive symptoms, their efficacy on negative 
symptoms, neurocognition, social functioning, and qual-
ity of life is limited,2–5 and their side effects impact treat-
ment adherence negatively.6 Poor knowledge regarding 
neurobiological mechanisms underlying psychotic dis-
orders has limited pharmacological targets to altered 
D2 neurotransmission
7 rather than more fundamental 
impairments. Despite improved understanding of the 
neurobiological bases of schizophrenia, developmentally 
informed pharmacology8,9 is not yet available. Therefore 
identification of new drug targets and mechanisms is 
needed.
Recent data suggest a convergence of redox dysregu-
lation and oxidative stress in promoting the emergence 
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of psychosis. This mechanism, along with neuroinflam-
mation, NMDA receptor hypofunction, and dopamine 
dysregulation, may belong to a central pathophysiologi-
cal hub: an imbalance within any of these systems would 
lead to micro- and macro-circuitry brain defects involving 
alterations of parvalbumin interneurons and white matter 
and leading to connectivity and clinical impairments.10–12 
Indeed, recent research identified increases in oxidative 
stress in blood, plasma, cerebrospinal fluid (CSF) and 
postmortem samples of schizophrenia patients, including 
increased lipid and protein oxidation and alterations in 
antioxidant defense systems, such as catalase and super-
oxide dismutase.13–17 In particular, glutathione (GSH) sys-
tem deficits are linked to schizophrenia pathophysiology in 
many ways. GSH levels are lower in chronic schizophrenia, 
as detected in CSF, in postmortem brain, and by magnetic 
resonance spectroscopy (MRS)-based in vivo imaging, low 
cortical GSH levels being associated with worse negative 
symptoms.18–21 Moreover, the GSH redox enzymes, GSH 
peroxidase (GPx) and GSH reductase (GR) are also dys-
regulated.22 Genetic evidence highlights a role for GSH 
system impairment in schizophrenia etiopathology: copy 
number and allelic variants of glutathione-s-transferase 
(GST) genes23 and of key GSH synthesizing genes are 
associated with the disease24 and lead to functional con-
sequences.25 A randomized controlled add-on trial (RCT) 
with N-acetylcysteine (NAC), an antioxidant and pre-
cursor of GSH, in patients with chronic schizophrenia26 
showed that NAC led to significant reductions in negative 
symptoms and medication side effects. In addition, a study 
based on a subsample showed that NAC improved EEG 
local synchronization27 and mismatch negativity.28 An 
independent add-on trial to risperidone also demonstrated 
that negative symptoms in patients with chronic schizo-
phrenia improved with NAC.29 While actionable biomark-
ers in schizophrenia are currently scarce,30 they may allow 
the identification of patients responding to treatments tar-
geting specific pathophysiological mechanisms.
In genetic or developmental rodent models of schizo-
phrenia presenting oxidative stress-induced parvalbumin 
interneuron impairment, NAC administered during brain 
development prevented the deleterious and permanent 
effects of early insults.31,32 This suggests oxidative stress’ 
negative impact on parvalbumin interneurons and myelin-
ation may occur early in the illness trajectory, thus explain-
ing the modest impact of NAC in chronic schizophrenia 
patients. The current RCT was therefore launched in early 
psychosis (EP) patients. Our aims were, first, to determine 
whether the addition of NAC to standard medication 
would improve negative symptoms in EP patients; second, 
to explore the impact of NAC on positive symptoms and 
neurocognition, the latter being critical for functional out-
come33–36; third, to explore whether NAC would modulate 
brain GSH levels and improve or normalize blood gluta-
thione/redox dysregulation profile, at least in a subgroup 
of patients, in order respectively to clarify the controversial 
ability of NAC to cross the blood brain barrier37–40 and to 
explore whether the response to NAC might be associated 
with glutathione-related peripheral biomarkers; fourth, to 
explore impact of NAC treatment on brain levels of glu-
tamate (Glu), glutamine (Gln), Gln/Glu, and myoinositol 
(Ins), which were normalized by NAC in a previous study 
of glutathione-deficient schizophrenia mouse model.41
Materials, Subjects, and Methods
Study Design and Participants
The study, conducted in 2009–2014, was a 6-months, ran-
domized, placebo-controlled, double-blind, 2-center trial 
comparing NAC and placebo as add-on therapy to stand-
ard medication (antipsychotics, mood stabilizers, and/or 
benzodiazepine). Participants were recruited from the 
Treatment and Early Intervention in Psychosis Program 
(TIPP, Lausanne University Hospital, Switzerland42) and 
the Commonwealth Research Center of the Beth Israel 
Deaconess Medical Center Department of Psychiatry 
(Harvard Medical School, Boston, USA). Inclusion cri-
teria were (1) male or female aged 18–40; (2) having a 
psychotic disorder, defined by reaching the “psychosis 
threshold” subscale on the Comprehensive Assessment 
of At Risk Mental States scale (CAARMS); (3) less than 
12  months of treatment for psychosis; (4) capability to 
provide informed consent; and (5) sufficient stability 
to participate in the study. Disease duration is the time 
between first psychotic symptoms and entry into the trial. 
The diagnosis was based on DSM-IV criteria.43 (Ethics, 
power calculation, exclusion criteria: see supplement.)
Study Medication
NAC was provided by Bioadvantex Pharma, Inc. and 
produced under Good Manufacturing Practice condi-
tions. Stability of the compound was ascertained, and 
the integrity of the active agent was protected by sep-
arate dose packaging. All participants were random-
ized in a 1:1 allocation ratio to either NAC effervescent 
tablets (900 mg) at a dosage of 2700 mg/day (morning: 
1800 mg; evening: 900 mg) or matching placebo tablets 
before meals. Tablets were dispensed every month, from 
visit 1 to 7. At each visit, remaining tablets were counted 
to assess adherence over the past month; adherence was 
considered as poor when less than 25% of the monthly 
dose was taken (less than 675  mg/day) (dose rationale, 
randomization, and masking: see supplement).
Study Visits, Evaluation, and Outcomes
Eight visits were conducted including a baseline visit (V1) 
at NAC initiation, monthly visits thereafter (V2–V7), and 
an additional visit after 1 month postdiscontinuation (V8).
Raters were psychologists with regular training for 
interrater reliability. The primary outcome was the 
PANSS negative score (PANSS−). Secondary outcomes, 
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assessed on a monthly basis (V1–V8), included PANSS 
positive (PANSS+), PANSS general, functioning assessed 
by the Global Assessment of Functioning (GAF) and 
Social Functioning Assessment Scale (SOFAS) scales, 
and relapse rate. After controlling for adherence (see sup-
plement), dosages of antipsychotic medication were con-
verted to chlorpromazine equivalents44,45 and included as 
a covariate in statistical models. Medication side effects 
were assessed at V1, V3, V7, and V8 with the Udvalg 
for Kliniske Undergelser (UKU) scale.46 Adjusted item 
scores were calculated as differences from baseline val-
ues to account for pretreatment differences; we attributed 
zero to negative differences as recommended.46
Neurocognitive Measures
The MATRICS Consensus Cognitive Battery (MCCB33,34) 
was assessed at V1 and V7, excluding the Mayer-Salovey-
Caruso Emotional Intelligence Test (MSCEIT), which 
does not “translate” well into French as an index of social 
cognition. Thus, 9 of 10 subtests were given, comprising 
6 factors namely processing speed, sustained attention, 
working memory, verbal learning, visual learning, and 
problem solving.
Central and Peripheral Biochemical Assessments
Levels of GSH in medial prefrontal cortex (GSHmPFC) 
were assessed in a subset of participants by 1H-MRS 
before (V1) and at the end of 6 months of NAC/placebo 
supplementation (V7). 1H-MRS measurements were per-
formed as previously described47,48 (supplement).
Blood markers of the glutathione synthesis and redox 
system (plasmatic Cysteine, CYSPl; blood cells GSH, 
GSHBC; GPx enzymatic activity in blood cells, GPxBC) 
were measured at the Lausanne site at V1, V3, and V7 
according to standardized procedures described previ-
ously49–51 (supplement).
Statistical Analysis
We included 90% observations (27/263 excluded due to 
nonadherence). We investigated if  the missing obser-
vations at each time point are “Missing Completely 
At Random” (MCAR) using Little’s MCAR test in 
R. Missing data at baseline and at 6 months are MCAR. 
Missing data at 2 months of treatment are not MCAR, 
in particular, because the pattern of missing data was dif-
ferent at the 2 sites. But the test supports the MCAR for 
observations corresponding to 2 months at Lausanne.
Differences in improvement rate during follow-up were 
estimated using a 2-level random intercept and random 
slope model, the treatment being tested as a predictor.
A series of  marginal tests were performed to inves-
tigate associations among demographic variables and 
baseline scores between groups. Mean values and stand-
ard errors are reported for continuous variables; t-tests 
were applied to assess the significance of  differences 
between groups.
For neurocognitive outcomes, analyses were conducted 
on MCCB standardized scores (t-scores). Repeated 
measures ANOVA were performed with group (NAC) as 
a between-group factor and time as a within-group fac-
tor. A significant time × group interaction would indicate 
that rate of improvement in cognition over assessments 
differed between groups.
Considering that response to NAC supplementation 
may be linked to baseline redox status, we performed addi-
tional analyses based on Classification and Regression 
Trees (CARTs)52 to explore whether baseline redox level 
was benefiting from NAC supplementation. CARTs are 
powerful and flexible machine learning tools used here 
to single out which variables are best associated with an 
improvement in the outcome. Once a potential threshold 
level was identified, a longitudinal model was fitted to the 
PANSS scores for patients treated with NAC.
Results
Demographic Characteristics at Baseline
Of 302 patients screened for eligibility, 63 were random-
ized (figure 1A); 32 to NAC (6 in Boston, 26 in Lausanne) 
and 31 to placebo (4 in Boston, 27 in Lausanne). After 
randomization, 2 patients were excluded (one because of 
white matter lesions detected on baseline MRI, and one 
withdrew consent). All existing data were used in the esti-
mation of the models including patients with data only 
at baseline. Missing data were MCAR and imputation 
methods were not used. Diagnostic repartition was sim-
ilar in both groups with predominance of schizophrenia 
(68% and 63%, see supplementary table 1).
Baseline clinical characteristics and antipsychotic dos-
ages are reported in table 1. No significant between-group 
differences were observed in baseline characteristics 
including negative symptom levels, which were moderate 
in severity. For redox markers, basal GSHmPFC levels were 
lower in NAC than the placebo group. Moreover, values 
from both sites were within the same range and were thus 
pooled together (supplementary figure  1). Dosages of 
antipsychotics expressed in chlorpromazine equivalent, 
percentage of smokers, and levels of various blood mark-
ers were similar in both groups. The numbers of patients 
for each antipsychotic at baseline are detailed in supple-
mentary table 2.
Clinical Outcome
There were no significant differences between groups 
on change in negative symptoms (PANSS−; β  =  0.161, 
SE  =  0.237, P  =  .50), positive symptoms (PANSS+; 
β = 0.176, SE = 0.207, P = .39), general symptomatology 
(PANSS general score; β = 0.598, SE = 0.359, P = .09), 
or functional outcome (GAF; β  =  −0332, SE  =  0.515, 
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P =  .52 and SOFAS; β = −0.196, SE = 0.527, P =  .71) 
(figure 1B–C). Results remained the same when control-
ling for age, sex, duration of illness at baseline, and level 
of co-medication based on chlorpromazine equivalents.
Neurocognition
NAC improved cognitive speed in both the verbal fluency 
(F[1, 28] = 5.75, P = .023, ηp2  = 0.17) and the trail mak-
ing A (F[1, 28] = 4.28, P = .048, ηp2  = 0.13) tests, and in 
the processing speed (PS) factor containing these tasks 
(F[1, 28] = 5.85, P = .022, ηp2  = 0.17; figure 2A–D). Symbol 
coding, the third task in the PS factor, did not change signif-
icantly (F[1, 27] = 0.710, P = .407, ηp2  = 0.03). Improvement 
in PS was significantly correlated with a decrease in nega-
tive symptoms in NAC-treated patients (PS factor: r = .491, 
P = .047; verbal fluency: r = .546, P = .023; figure 2E–F). 
Other cognitive domains were unaffected, and results were 
the same when controlling for chlorpromazine equivalent 
antipsychotic dosage (supplementary table 3).
Peripheral and Central Biochemical Outcome Measures
Measurement of changes in GSHBC peripheral blood 
levels from baseline to month 6, using models adjusted 
for age and sex, revealed an average increase of 18.8% 
(SD = 50.2%) in patients receiving NAC while it decreased 
by 1.9% (SD = 48.7%) in the placebo group, leading to an 
overall difference of 17% (figure 3A, P = .05). No change 
in CysPL was found.
Paired t-tests indicate that GSHmPFC levels assessed 
by 1H-MRS increased after 6  months of  NAC 
Fig. 1. CONSORT flow diagram, primary and secondary outcomes. (A) Reasons for withdrawal from trial, 1white matter lesions 
detected at baseline MRI scan; 2withdrew at baseline; 3lack of motivation; 4side effects. (B) Change in PANSS− score vs baseline in NAC 
(red circles) and placebo (green triangles) groups at each visit. (C) Comparison of NAC vs placebo in the rate of improvement. PANSS, 
Positive and Negative Syndrome Scale; GAF, General Assessment of Functioning; SOFAS, Social and Occupational Functioning 
Assessment Scale; β, an estimate of NAC effect vs placebo; SE, standard error.
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administration (mean percentage of  change: +22.6%; 
7 among 10 patients increased GSHmPFC by more than 
10%, P = .005), while it remained stable in the placebo 
group (mean percentage of  change: −4.6%; 1 among 11 
patients increased GSHmPFC by more than 10%), lead-
ing to an overall difference of  28% (figure  3B). This 
suggests that oral administration of  NAC affects brain 
GSH levels. However, we cannot rule out that a sponta-
neous increase of  brain GSH contributes to this effect 
in NAC-treated patients as their basal levels were lower 
than in the placebo group. Moreover, no changes in 
Glu, Gln, Gln/Glu, and Ins were observed in NAC or 
placebo groups (supplementary table 4).
NAC Improves Positive Symptoms in a Subsample of 
Patients
To explore whether patients with baseline peripheral redox 
dysregulation were more likely to benefit from NAC sup-
plementation, we performed exploratory analyses using 
CARTs among NAC-treated patients looking for the best 
predictors of clinical improvement after 2 months among 
baseline redox activity measures (ie, blood levels of GSHBC 
cysteine, homocysteine, glutamate, and enzymatic activity 
of GPxBC, GR and their ratio). Improvement in the positive 
PANSS score after 2 months of NAC treatment was highly 
associated with baseline GPxBC activity: patients with base-
line GPxBC activity higher than 22.3 U/g of Hb improved 
their PANSS+ scores at the second month and onwards 
(figure 4A). None of the tested variables were good predic-
tors of negative symptoms PANSS improvement.
A longitudinal model fitted to PANSS+ scores con-
firmed an improvement over time in NAC-treated 
patients with high baseline GPxBC compared to low base-
line GPxBC (P = .02, figure 4B, model fitted to patients 
with NAC). This difference remained significant after 
adjustment for disease duration and chlorpromazine 
equivalent doses. Among all participants having a high 
baseline GPxBC activity, a longitudinal improvement 
in PANSS+ was not observed in placebo, while a trend 
was seen under NAC (P = .07, figure 4B–C, model fitted 
to all patients), also after adjusting for disease duration 
and chlorpromazine equivalent doses. Furthermore, the 
change in GPxBC activity correlated negatively with the 
change of PANSS+ score showing that the positive symp-
toms improved when GPx activity remained stable. This 
was not observed in the placebo group (figure 4D). The 
correlation in the NAC group was significant at the sec-
ond month (r =− .76; P = .03) and a trend remained at 
the sixth month (r = −.63; P = .09, figure 4E).
Table 1. Clinical Information of Participants at Baseline and Medication Dosage During Trial
Variable Total (n = 61)
Treatment Group Statistics
P-valueNAC (n = 31) Placebo (n = 30) Test Statistics (df)
Age, mean (SD), y 25.4 (6.0) 26.1 (6.1) 24.7 (5.9) t(59) = 0.92 .36
Male, % (no.) 77% (47) 84% (26) 70% (21) χ2 (1) = 0.97 .33
Race (no.) 47 C, 12Af, 2 Ma 25 C, 5 Af, 1 Ma 22 C, 7 Af, 1Ma χ2 (2) = 0.98 .61
Smoking, % (no.) 56% (28) 45% (11) 65% (17) χ2 (1) = 1.94 .16
Body mass index, mean (SD) 25.09 (4.35) 25.3 (3.7) 24.8 (5.0) t(56) = 2.22 .68
Disorder duration, mean (SD), days 796 (726) 848 (767) 747 (693) t(56) = 0.53 .60
Antipsychotic medication
 Chlorpromazine equivalent, mean (SD) 309 (220) 309 (252) 309 (188) t(52) = 0.01 .99
 Changes of dose, mean (SD) 1.1 (1.1) 1.1 (1.1) 1.0 (1.2) z = −0.55 .58
 Changes of medication, mean (SD) 0.2 (0.5) 0.1 (0.3) 0.4 (0.6) z = −1.73 .08
Clinical scores
 Positive PANSS, mean (SD) 14.7 (5.6) 14.3 (5.4) 15.0 (5.6) t(58) = -0.47 .64
 Negative PANSS, mean (SD) 16.4 (5.7) 15.6 (5.0) 17.3 (6.3) t(55) = −1.2 .23
 GAF, mean (SD) 52.8 (11.8) 54.0 (10.8) 51.6 (12.8) t(57) = 0.78 .44
 SOFAS, mean (SD) 54.7 (12.0) 55.8 (11.0) 53.5 (13.0) t(57) = 0.76 .45
Blood markers
 Cysteine, mean (SD), uM 257.7 (35.7) 261.3 (37.6) 254.0 (33.6) t(58) = 0.79 .43
 Glutathione, mean (SD), mM 0.81 (0.24) 0.77 (0.21) 0.84 (0.27) t(47) = −1.04 .31
 GPx activity, mean (SD), µmol/min/gHb 21.13 (7.17) 21.24 (7.50) 21.01 (6.93) t(58) = 0.12 .90
Brain markers Total (n = 25) NAC (n = 13) Placebo (n = 12)
 Glutathione, mean (SD), mM 0.99 (0.24) 0.87 (0.23) 1.12 (0.18) t(22) = −3.13 .005
 Glutamate, mean (SD), mM 10.37 (1.04) 10.12 (0.80) 10.64 (1.23) t(19) = −1.23 .234
 Glutamine, mean (SD), mM 3.09 (0.51) 3.25 (0.51) 2.93 (0.48) t(23) = 1.58 .128
 myo-Inositol, mean (SD), mM 6.27 (0.85) 6.25 (1.05) 6.28 (0.62) t(20) = −0.07 .941
Note: Antipsychotic medication is expressed in chlorpromazine equivalents. df, degree of freedom; Hb, hemoglobin; SD, standard 
deviation; no., number; C, Caucasian; Af, African; Ma, Maghreb; PANSS, Positive and Negative Syndrome Scale; GAF, General 
Assessment of Functioning; SOFAS, Social and Occupational Functioning Assessment Scale.
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Side Effects and Postdiscontinuation Data
There were no significant side effects of NAC as meas-
ured by the UKU scale (supplementary table  5). The 
effect of NAC on GSHBC at 6 months was lost upon wash-
out (7th month, P = .55 after adjustment for age and sex, 
figure 4C). Mean PANSS+ scores changes were similar 
in NAC- and placebo-treated groups after treatment dis-
continuation (P = .52). In patients with high basal GPxBC, 
mean PANSS+ scores changes were 74% greater after dis-
continuation of NAC compared to placebo, however, this 
was not significant (figure 4C, P = .48).
Discussion
This first RCT assessing the impact of NAC treatment in 
a sample of EP patients and the potential predictive role 
of peripheral biomarkers of redox dysregulation yielded 
3 main findings. First, the addition of NAC to standard 
treatment in an unselected sample of patients improved 
neither symptomatic nor functional outcome. Second, 
oral administration of NAC increased glutathione lev-
els in the brain and improved neurocognition, namely 
processing speed. Third, redox peripheral index based on 
blood cells GPx activity identified EP patients displaying 
a significant response to NAC in their positive symptoms.
Considering the impact observed in a larger sample 
of 140 chronic patients,26 we hypothesized that NAC 
would be more beneficial on negative symptoms in an 
earlier phase of illness, when the adverse impact of redox 
dysregulation is still unfolding. However, this was not 
confirmed in this small sample. Besides the obvious lim-
itation of sample size, it must be mentioned that modest 
baseline negative symptoms levels limited the range for 
improvement in this domain.
Regarding neurocognition, all significant improve-
ments were observed in the same cognitive domain 
(processing speed). While multiple comparisons suggest 
these results need replication, overall 2 out of  9 MCCB 
Fig. 2. Effect of NAC vs placebo on processing speed’s measures. Evolution of trail making test (A), verbal fluency (B), processing speed 
factor T-scores (C) in NAC (red circles), and placebo (green triangles) groups. (D) Statistical comparison between NAC and placebo 
groups; partial-eta-square ( ηp2 ) indicates the effect size. Linear correlations between changes in PANSS− and changes in processing speed 
factor (E) and verbal fluency T-scores (F) in NAC-treated patients.
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tests (1 of  6 factors) were significant in this study which 
is above what could be expected by chance. Indeed, per-
forming 9 tests with an alpha level set to 0.05 in each 
case would lead on average to 9 × 0.05 = 0.45, ie, less 
than one false positive under the null hypothesis (no 
difference). As 2 cognitive tasks were significant and as 
they are all in the same cognitive domain, we can argue 
that there are likely real differences for processing speed. 
This dimension was assessed by a third task (symbol 
coding) which was not improved by NAC. However, this 
task also involves new learning which the 2 other tests 
do not. Nevertheless, this promising finding must be 
replicated in a larger sample.
The demonstration of an increase in cerebral GSH lev-
els in vivo after 6 months oral administration of NAC is 
important considering the low bioavailability of NAC53 
and its debated capability to cross the blood–brain bar-
rier.37–40 An increase of cerebral GSH levels has also 
been confirmed with a single intravenous administration 
of NAC in healthy controls, patients with Parkinson’s 
diseases and Gaucher disease.54 NAC is known to be 
hydrolyzed into cysteine, the limiting precursor for GSH 
synthesis. Considering GSH’s limited ability to cross the 
blood–brain barrier and the absence of elevation of cys-
teine in patients’ blood, increased brain GSH may be 
linked to transport of NAC rather than cysteine across 
the blood–brain barrier, an important finding regarding 
treatment development.
In a previous study of the glutathione-deficient schizo-
phrenia mouse model, NAC treatment also led to neuro-
chemical changes including glutamate (Glu), glutamine 
(Gln), Gln/Glu and myoinositol.41 However, the effect of 
NAC on these metabolites was not observed in the cur-
rent trial, either implying that NAC does not have the 
same normalizing effect in EP patients or that neuro-
chemical alterations present at this illness stage are not 
reversible. The observation that NAC normalized most 
neurochemical alterations in peripubertal animal models 
to normal levels suggests NAC should be tried in indi-
viduals at ultra high risk for psychosis, ie, at an earlier 
developmental stage.
The correlation between improvement in PANSS+ 
score and changes of  peripheral redox markers such as 
GPxBC, in association with brain GSH levels are impor-
tant findings. Indeed, we observed previously a nega-
tive correlation between GSHmPFC and GPxBC activity 
showing that low GSHmPFC was associated with high 
GPxBC reflecting high oxidation status.
55 In many fields 
of  medicine, treatment monitoring is based not only on 
the symptomatic response, but also on modifications of 
biological markers.56 We showed here for the first time 
that NAC administration modified peripheral redox 
status which paralleled clinical improvement. For clin-
ical characteristics like body mass index and smoking, 
which are known to influence redox status and cogni-
tion, no differences between groups at baseline and at 
the end of  treatment were observed. Moreover, smok-
ing status and NAC add-on treatment seemed to affect 
different cognitive skills. Our results on the effects of 
NAC are not accounted for by body mass index or 
smoking.
Moreover, our results suggest that peripheral redox 
status allows the identification of a patient subgroup 
benefiting from NAC supplementation. The best GPxBC 
blood level to segregate responders from nonresponders 
in our small sample was 22.3 U/gHb, but this should be 
refined and confirmed in larger independent cohorts. 
Fig. 3. Effect of NAC vs placebo on GSH levels. (A) Boxplot 
illustrating changes vs baseline in GSHBC after 2 and 6 months 
and after washout (7 months) of treatment with NAC (gray 
boxes) or placebo (white boxes). (B) GSHmPFC levels in patients 
with NAC (n = 12, red circles, left) or placebo (n = 12, green 
triangles, right).
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This replication study should clarify if  GPx peripheral 
redox marker reflects brain function. It is notable that in 
high GPxBC patients, NAC effect on PANSS+ score was 
already reached after 2 months, suggesting a 2–3 months 
supplementation with NAC might be sufficient in a vali-
dation study within a larger cohort.
Fig. 4. Additional analysis by classification and regression tree. (A) Illustration of the classification based on GPxBC enzymatic activity 
in the NAC group: 36% of patients have an activity at baseline above 22.3 U/g of Hb associated with a mean decrease of PANSS+ score 
of −5.8 points; 64% of patients have an activity at baseline below 22.3 U/g of Hb associated with a mean improvement of PANSS+ score 
of −1.5 point. (B) Effect of NAC add-on treatment on PANSS+ scores on patients with baseline activity of GPxBC above 22.3 U/g of 
Hb. Values are coefficients of each factor in the linear model. SE, standard error. P-values under 0.1 are indicated in bold. (C) Evolution 
of PANSS+ scores vs baseline in patients with low (left) or high (right) basal activity of GPxBC in NAC (red circles) or placebo (green 
triangles) groups during the trial (1–6 months) and after washout (7 months). (D, E) Changes in PANSS+ scores vs baseline and changes 
in GPxBC activity vs baseline is illustrated by linear correlation in patients with basal activity of GPxBC above 22.3 U/g of Hb. Patients 
under NAC (left) or Placebo (right) at 2 (D) and 6 months (E). Dots depict individual values, gray zones 95% confidence intervals.
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There are limitations to this trial. First, these conclu-
sions come from post hoc analyses, and therefore a pro-
spective hypothesis testing trial is needed to confirm them. 
Second, the sample size is relatively small, and we may 
have failed to find significant differences for that reason. 
The MRS study was limited to 12–13 subjects per group, 
as many patients declined to participate in this more 
demanding investigation. Third, the severity of baseline 
negative symptoms was relatively modest, leaving lim-
ited room for improvement. Finally, the finding that only 
36% of the patients might respond to NAC based on high 
GPxBC implies that the power of our study was lower than 
initially estimated, due to a large prevalence of a nonre-
sponder phenotype. This also suggests that early phases 
of the disease could be associated with phenotypic het-
erogeneity which would need valid biomarker-guided 
treatments.
Conclusion
We believe this to be an important step toward bio-
marker-guided treatment, as it might allow identifying 
a subgroup of patients susceptible to benefit from NAC 
treatment. While this trial of NAC administration as an 
add-on to standard antipsychotic treatment in a sample 
of EP patients failed to show global benefits on nega-
tive symptoms, secondary analyses showed that NAC 
improves processing speed and positive symptoms in sub-
jects who display a certain level of redox dysregulation 
assessed by peripheral markers at baseline. This fits well 
with the concept that schizophrenia may be composed 
of various endophenotypes based on different neurobi-
ological mechanisms57 responding to distinct treatments, 
and represents a relevant step in the development of bio-
marker-guided treatment with a redox regulator in EP.
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Supplementary data are available at Schizophrenia 
Bulletin online.
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